Melatonin and vitamin D 3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells

Journal of Pineal Research

Volumn 50, Issue 2, 2011, Pages 150-158

  Proietti, Sara ^a   Cucina, Alessandra ^b   D'Anselmi, Fabrizio ^b,c   Dinicola, Simona ^a   Pasqualato, Alessia ^d   Lisi, Elisabetta ^e   Bizzarri, Mariano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ITALIAN SPACE AGENCY   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e ROMA TRE UNIVERSITY   (Italy)

Author keywords

Akt; MDM2; melatonin; Smad3; transforming growth factor beta 1; vitamin D3

Indexed keywords

COLECALCIFEROL; MELATONIN; PROTEIN KINASE B; PROTEIN MDM2; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; MDM2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOSTASIS; DENSITOMETRY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECALCIFEROL; DRUG SYNERGISM; HUMANS; MELATONIN; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79951596975     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00824.x     Document Type: Article

References (44)

1. Korkmaz A, Sanchez-Barcelo EJ, Tan DX, Reiter RJ,. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res Treat 2009; 115: 13-27.
2. Reiter R.J,. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37: 213-214. (Pubitemid 39274120)
3. Colston KW, Hansen CM,. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002; 9: 45-59. (Pubitemid 34298363)
4. Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery. Mol Endocrinol 2001; 15: 1370-1380. (Pubitemid 32703484)
5. Lin R, White JH,. The pleiotropic actions of vitamin D. Bioessays 2004; 26: 21-28. (Pubitemid 38095345)
6. Momand J, Jung D, Wilzynski S, Niland J,. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453-3459. (Pubitemid 28347214)
7. Bond GL, Hu W, Levine AJ,. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8. (Pubitemid 40321795)
8. Piette J, Neel H, Marechal V,. Mdm2: keeping p53 under control. Oncogene 1997; 15: 1001-1010. (Pubitemid 27401954)
9. Wasylyk C, Salvi R, Argentini M, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18: 1921-1934. (Pubitemid 29150079)
10. Bianco R, Ciardiello F, Tortora G,. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets 2005; 5: 51-56. (Pubitemid 40321800)
11. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559. (Pubitemid 40799248)
12. Cucina A, Proietti S, Danselmi F, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46: 172-180.
13. Thompson T, Andreeff M, Studzinski GP, et al. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther 2010; 9: 1158-1168.
14. Levine AJ,. p53, the Cellular Gatekeeper for Growth and Division. Cell 1997; 88: 323-331. (Pubitemid 27131374)
15. Mediavilla MD, Cos S, Sanchez-Barcelo EJ,. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65: 415-420. (Pubitemid 29325284)
16. Koli K, Keski-Oja J,. 1,25-Dihydroxyvitamin D3 Enhances the Expression of Transforming Growth Factor and Its Latent Form Binding Protein in Cultured Breast Carcinoma Cells. Cancer Res 1995; 55: 1540-1546.
17. Bizzarri M, Cucina A, Valente MG, et al. Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. J Surg Res 2003; 110: 332-337. (Pubitemid 36683032)
18. Strober W,. Trypan blue exclusion test of cell viability. Curr Protoc Immunol 1997; (Suppl. 21):A.3B.1-A.3B.2.
19. Kruger NJ,. The Bradford method for protein quantitation. Methods Mol Biol 1994; 32: 9-15.
20. Duronio V,. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-344.
21. Yang WL, Wu CY, Wu J, et al. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010; 9: 487-497.
22. Gasco M, Shami S, Crook T,. The p53 pathway in breast cancer. Breast Cancer Res 2002; 4: 70-76. (Pubitemid 34248123)
23. Chene P,. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 103-109.
24. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014. (Pubitemid 28408466)
25. Leri A, Liu Y, Claudio PP, et al. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 1999; 154: 567-580. (Pubitemid 29094106)
26. Mayo LD, Donner DB,. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001; 98: 11598-11603. (Pubitemid 32928774)
27. Iwakuma T, Lozano G,. MDM2, an introduction. Mol Cancer Res 2003; 1: 993-1000. (Pubitemid 38044974)
28. Eischen CM, Lozano G,. p53 and MDM2: antagonists or partners in crime? Cancer Cell 2009; 15: 161-162.
29. Schmierer B, Hill CS,. Kinetic analysis of Smad nucleocytoplasmic shuttling reveals a mechanism for transforming growth factor beta dependent nuclear accumulation of Smads. Mol Cell Biol 2005; 25: 9845-9858. (Pubitemid 41572734)
30. Seoane J,. p21(WAF1/CIP1) at the switch between the anti-oncogenic and oncogenic faces of TGFbeta. Cancer Biol Ther 2004; 3: 226-227. (Pubitemid 41350909)
31. Dupont S, Zacchigna L, Adorno M, et al. Convergence of p53 and TGF-beta signalling networks. Cancer Lett 2004; 213: 129-138. (Pubitemid 39140970)
32. Xie W, Mertens JC, Reiss DJ, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002; 62: 497-505. (Pubitemid 34106424)
33. Pardali K, Moustakas A,. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775: 21-62. (Pubitemid 44881193)
34. Han SU, Kim HT, Seong Do H, et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 2004; 23: 1333-1341.
35. Buck MB, Pfizenmaier K, Knabbe C,. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 2004; 18: 1643-1657. (Pubitemid 38859573)
36. Matsuda T, Yamamoto T, Muraguchi A, et al. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. Biol Chem 2001; 276: 42908-42914.
37. Wu L, Wu Y, Gathings B, et al. Smad4 as a transcription corepressor for estrogen receptor alpha. Biol Chem 2003; 278: 15192-15200. (Pubitemid 36799854)
38. Ewan KB, Henshall-Powell RL, Ravani SA, et al. Transforming growth factor-β1 mediates cellular response to DNA damage in situ. Cancer Res 2002; 62: 5627-5631. (Pubitemid 35204711)
39. Ganguli G, Wasylyk B,. p53-independent functions of MDM2. Mol Cancer Res 2003; 1: 1027-1035. (Pubitemid 38044978)
40. Kinyamu HK, Archer TK,. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 2003; 23: 5867-5881. (Pubitemid 36951348)
41. Levav-Cohen Y, Haupt S, Haupt Y,. Mdm2 in growth signaling and cancer. Growth Factors 2005; 23: 183-192. (Pubitemid 43203049)
42. Blain SW, Massague J,. Different Sensitivity of the Transforming Growth Factor-beta Cell Cycle Arrest Pathway to c-Myc and MDM-2. J Biol Chem 2000; 275: 32066-32070.
43. Fakharzadeh SS, Trusko SP, George DL,. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565-1569. (Pubitemid 21905621)
44. Alvarez RH, Valero V, Hortobagyi GN,. Emerging targeted therapies for breast cancer. J Clin Oncol 2010; 28: 3366-3379.